PATH Malaria Vaccine Initiative creates reference lab

PATH Malaria Vaccine Initiative created a new central reference lab to standardize the ability to measure performance of various malaria vaccine formulations. The addition comes in the form of a collaboration with the International AIDS Vaccine Initiative and Imperial College London. The idea is to determine the ability of different vaccine candidates in human clinical testing to elicit an immune response with the goal of protecting against deadly malaria parasites. Release

Suggested Articles

BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.

BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.